About Immunovia ab
Immunovia AB: Revolutionizing Blood-Based Diagnosis for Complex Diseases
Immunovia AB is a Swedish biotech company that is dedicated to revolutionizing blood-based diagnosis and improving survival rates for patients with complex diseases. The company was founded in 2007 by researchers from Lund University, who had a vision of developing innovative diagnostic tools that could detect diseases at an early stage, when they are most treatable.
Since its inception, Immunovia has been at the forefront of research and development in the field of biomarker-based diagnostics. The company's flagship product, IMMray™ PanCan-d, is a blood test that can detect pancreatic cancer at an early stage with high accuracy. This breakthrough technology has the potential to save thousands of lives each year by enabling earlier detection and treatment of this deadly disease.
In addition to pancreatic cancer, Immunovia is also developing diagnostic tests for other complex diseases such as autoimmune disorders and inflammatory bowel disease (IBD). These tests are based on the same core technology as IMMray™ PanCan-d – a unique combination of antibody microarray analysis and machine learning algorithms – which allows for highly accurate detection of disease-specific biomarkers in blood samples.
One key advantage of Immunovia's approach is that it enables non-invasive diagnosis using just a small sample of blood. This makes it easier and less stressful for patients to undergo testing compared to traditional methods such as tissue biopsies or invasive procedures.
Another advantage is that Immunovia's tests have the potential to be used not only for diagnosis but also for monitoring disease progression and response to treatment. This could help doctors tailor treatments more effectively based on individual patient needs, leading to better outcomes overall.
Immunovia has received numerous awards and accolades over the years in recognition of its groundbreaking work in biomarker-based diagnostics. In 2018, the company was named one of Europe's top ten most innovative companies by Fast Company magazine. It has also been recognized by Frost & Sullivan as a leader in pancreatic cancer diagnostics.
Looking ahead, Immunovia plans to continue expanding its portfolio of diagnostic tests while also exploring new applications for its core technology platform. With its focus on innovation and commitment to improving patient outcomes, this Swedish biotech firm looks set to remain at the forefront of biomarker-based diagnostics well into the future.
immunovia.com